United Kingdom — National Health Service & Palantir

United Kingdom — National Health Service: The United Kingdom — National Health Service>>> is undergoing a review of its contract with Palantir>>> due to concerns about patient confidentiality, public trust, and reliance on a U.S. supplier.

Palantir: Palantir is facing significant scrutiny over its contract with the United Kingdom — National Health Service>>> and its stock has seen pullbacks due to concerns about its public sector role and ethical considerations.

United Kingdom — National Health Service: The NHS contract with Palantir is under review, adding to the company's regulatory challenges in the UK.

Palantir: Palantir is challenging the blocked contract and faces scrutiny over its NHS contract. The outcome could affect its UK and European business prospects.

United Kingdom — National Health Service: The United Kingdom — National Health Service in the United Kingdom is reviewing its $441 million contract with Palantir, creating uncertainty for Palantir's international government business.

Palantir: Palantir is the central entity of this event, with its stock performance, financial results, and valuation being the primary focus of the articles. The company has experienced significant revenue growth, particularly in its U.S. commercial segment, driven by its Artificial Intelligence Platform (AIP).

United Kingdom — National Health Service: British lawmakers have called for the United Kingdom — National Health Service to end its contract with Palantir, indicating a broader European trend of re-evaluating reliance on US tech firms.

Palantir: Palantir' contract with the France — Directorate-General for Internal Security has been terminated in favor of a domestic provider, reflecting a growing European wariness of relying on US tech platforms. This decision, along with similar actions in other European countries, negatively impacts Palantir' market position and future revenue prospects in the European public sector.

United Kingdom — National Health Service: The NHS is a potential customer for Quantexa's single patient record programme, which could improve data management but also raises data sovereignty concerns.

Palantir: Palantir is mentioned as a US rival in the UK public sector market, but the event does not directly affect it.